Perseus to Develop Europe’s First AI Powered Electric Vehicle
25.9.2025 18:35:00 CEST | Business Wire | Press Release
Perseus Motor Corporation, Europe’s first AI-native EV brand, today announced a landmark strategic alliance with SODA.Auto, a leader in AI and Software Defined Vehicles, to co-develop the world’s most advanced AI powered Human–Machine Interface (HMI). This partnership marks a decisive step toward redefining the relationship between humans and vehicles in the era of intelligent mobility.
“Perseus was founded through a realization that today’s car is passive and isolated, while I wanted a vehicle that could seamlessly partner with my busy day-to-day world. I envisioned a vehicle that thinks, adapts, and evolves around its driver,” said Mohammed Yehya El Bakkali, Founder and CEO of Perseus Motor Corporation. “This alliance with SODA.Auto transforms that vision into reality. Together, we are building the most advanced driver–vehicle interface in the world.”
Unlike traditional automakers, Perseus is pioneering a future where AI shapes every interaction between driver and vehicle. The result is a car that functions as a living intelligence system, delivering a uniquely personalized driving experience where AI does not just assist the driver; it learns about them, understands them, and attunes itself to their journeys, forming a truly symbiotic relationship.
The car will dynamically learn the owner’s driving style and adjust itself to their emotional state to improve safety. It will also learn their driving routines and preferences, proactively adapting and fine tuning itself to reduce the driver’s cognitive load in their busy day-to-day lives. This makes every Perseus vehicle as unique as its owner.
Under the alliance, Perseus will lead conceptualization, design, and product definition, embedding AI as the core layer of its vehicle architecture. The two companies will operate joint R&D centres in Masdar City, Abu Dhabi, and Bicester, Oxfordshire. These facilities will combine world-class AI engineering talent, software specialists, and advanced digital and physical testing environments to accelerate development.
“Partnering with Perseus allows us to unite around a shared AI strategy and apply it in extraordinary new vehicles,” said Sergey Malygin, CEO of SODA.Auto. “The outcome will be a step change in how humans interact with vehicles: intelligent, intuitive, and deeply personal. This is Europe setting the global benchmark.”
The Perseus and SODA.Auto alliance comes at a time when the global automotive industry is focused narrowly on electrification and autonomy. Perseus is positioning AI powered interaction as the defining competitive advantage of the next decade.
Notes to Editors
About Perseus Motor Corporation
Perseus Motor Corporation is Europe’s first mass-premium AI-native electric vehicle brand. Headquartered in London, Perseus is pioneering the integration of artificial intelligence into the heart of the driving experience, creating vehicles that are adaptive, intelligent, and truly human centric.
About SODA.Auto
SODA.Auto is a software defined vehicle (SDV) technology company accelerating the development of next-generation mobility. Its platform combines an extensive SDV library of pre-certified software components with AI driven tools for simulation, validation, and integration. This enables automakers to create innovative vehicles up to ten times faster and at significantly lower cost. Headquartered in London, SODA.Auto is pioneering the fusion of SDV, AI, and digital twin technologies to deliver safe, intelligent, and future-ready automotive solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250925563851/en/
Contacts
Media contact: charlotte@the10group.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom